Double arm Clinical trial to evaluate the role of basti karma and virechan karma in hyperuricemia.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- The proportion of patients showing improvement in the level of Sr. Uric acid
研究概览
简要总结
A serum urate level over the top limit of the normal reference range is referred to as hyperuricemia, and it is thought to be a significant biochemical detection marker for the diagnosis of gout. Recent research indicates that gout and hyperuricemia are on the rise globally, and that this is significantly increasing the socioeconomic burden associated with them, including medical costs. In contemporary medicine, the standard of care consists of NSAIDs, colchicine, and glucosecocorticoids, which are commonly associated with negative side effects and fail to alter the course of the condition or treat it.According to acharya charak, The greatest treatment for the vatarakta is basti (enema). Basti (enema therapy) is the greatest option when this condition involves the leg, which is symptomatic of major vata vitiation. Every kind of vatarakta emphasizes the administration of ksheera vasti, the major ingredient being milk. Also, Snehayukta mridu virechak dravya should be utilized regularly after realizing that purisha obstructs the marga of vata.The goal of the current study is to assess how well Virechan and Basti work to lower uric acid levels in people with hyperuricemia.
According to reports, gout patients had considerably higher serum levels of pro-inflammatory cytokines such TNF-α and interleukin-6 (IL-6) than healthy controls. Additionally, this study is done to assess the relation between Sr. uric acid and IL-6 in patients of hyperuricemia and the effect of basti and virechan karma on the disease specific inflammatory cytokine IL-6.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients attending out patient department with Sr. Uric Acid levels greater than 7.0mg/dl will be enrolled in the study.
排除标准
- •Patients who are contraindicated for Basti karma will not be included in Group A and for those who are contraindicated for Virechan karma will not be included in Group B.
- •For both groups: Rectal prolapse, Fever, Pregnant and lactating mothers etc.
- •For Group A: Udar rog, intestinal perforation, intestinal obstruction etc.
- •For Group B: Loss of bowel control, atisara(diarrhea) etc Known case of Rheumatoid Arthritis, Psoriatic Arthritis Patients with renal or hepatic impairment (Sr creatinine greater than 1.8mg/dl along with Sr Urea greater than 60 mg/dl, SGOT and SGPT greater than Five times of upper limit Patients having LDL and Triglycerides greater than two times of upper limit Patients with co-morbid conditions such as Hypertension grade 2 greater than equal to 160/100mm of Hg) or more, Diabetes Mellitus (having HbA1c greater than 7.5% with or without hyperglycemicmedications Patients who are on anti tubercular or anti retroviral medication Patients requiring emergency treatment.
结局指标
主要结局
The proportion of patients showing improvement in the level of Sr. Uric acid
时间窗: At baseline. | 16th day | 31st day
post Basti karma and Virechan karma.
时间窗: At baseline. | 16th day | 31st day
次要结局
- The proportion of patients showing changes in the inflammatory cytokine IL-6 & CRP post Basti karma & Virechan karma.(At baseline)
- Assessment of features of vatarakta in patients of Hyperuricemia.(At baseline)
研究者
Dr Nitin Jindal
Ayurvedic and Unani Tibbia College and Hospital